396 related articles for article (PubMed ID: 12805500)
1. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.
Zhang L; Zhang ZG; Zhang RL; Lu M; Krams M; Chopp M
Stroke; 2003 Jul; 34(7):1790-5. PubMed ID: 12805500
[TBL] [Abstract][Full Text] [Related]
2. Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia.
Zhang L; Zhang ZG; Zhang RL; Lu M; Adams J; Elliott PJ; Chopp M
Stroke; 2001 Dec; 32(12):2926-31. PubMed ID: 11739997
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.
Yang Y; Li Q; Miyashita H; Howlett W; Siddiqui M; Shuaib A
J Neurosurg; 2000 May; 92(5):841-7. PubMed ID: 10794299
[TBL] [Abstract][Full Text] [Related]
4. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
Yang Y; Li Q; Yang T; Hussain M; Shuaib A
J Neurosurg; 2003 Feb; 98(2):397-403. PubMed ID: 12593629
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
6. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
Zhang L; Zhang ZG; Liu X; Hozeska A; Stagliano N; Riordan W; Lu M; Chopp M
Thromb Haemost; 2006 Jan; 95(1):166-73. PubMed ID: 16543976
[TBL] [Abstract][Full Text] [Related]
7. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.
Morris DC; Zhang L; Zhang ZG; Lu M; Berens KL; Brown PM; Chopp M
Stroke; 2001 Nov; 32(11):2635-40. PubMed ID: 11692028
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
[TBL] [Abstract][Full Text] [Related]
9. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model.
Shuaib A; Xu Wang C; Yang T; Noor R
Stroke; 2002 Dec; 33(12):3033-7. PubMed ID: 12468809
[TBL] [Abstract][Full Text] [Related]
10. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
Wang Y; Zhang Z; Chow N; Davis TP; Griffin JH; Chopp M; Zlokovic BV
Stroke; 2012 Sep; 43(9):2444-9. PubMed ID: 22811462
[TBL] [Abstract][Full Text] [Related]
11. Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat.
Zhang RL; Zhang ZG; Chopp M
Neurology; 1999 Jan; 52(2):273-9. PubMed ID: 9932943
[TBL] [Abstract][Full Text] [Related]
12. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
[TBL] [Abstract][Full Text] [Related]
13. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
Zhang L; Zhang ZG; Ding GL; Jiang Q; Liu X; Meng H; Hozeska A; Zhang C; Li L; Morris D; Zhang RL; Lu M; Chopp M
Circulation; 2005 Nov; 112(22):3486-94. PubMed ID: 16316970
[TBL] [Abstract][Full Text] [Related]
14. Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke.
Jiang Y; Fan X; Yu Z; Cheng C; Wang XS; Lo EH; Sun X; Wang X
Neurosci Lett; 2015 Aug; 602():73-8. PubMed ID: 26149229
[TBL] [Abstract][Full Text] [Related]
15. Thrombolysis with rhPro-UK 3 to 6 hours after embolic stroke in rat.
Hao CH; Ding WX; Sun Q; Li XX; Wang WT; Zhao ZY; Tang LD
Neurol Res; 2019 Nov; 41(11):1034-1042. PubMed ID: 31584350
[No Abstract] [Full Text] [Related]
16. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain.
Zhang RL; Zhang ZG; Chopp M; Zivin JA
Stroke; 1999 Mar; 30(3):624-9. PubMed ID: 10066862
[TBL] [Abstract][Full Text] [Related]
17. Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Jin R; Xiao AY; Liu S; Wang M; Li G
Stroke; 2018 Jul; 49(7):1708-1718. PubMed ID: 29844028
[TBL] [Abstract][Full Text] [Related]
18. Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
Lapchak PA; Zivin JA
Stroke; 2003 Aug; 34(8):2013-8. PubMed ID: 12855833
[TBL] [Abstract][Full Text] [Related]
19. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor.
Ding G; Jiang Q; Zhang L; Zhang ZG; Li L; Knight RA; Ewing JR; Wang Y; Chopp M
J Cereb Blood Flow Metab; 2005 Jan; 25(1):87-97. PubMed ID: 15678115
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke.
Zhang L; Chopp M; Teng H; Ding G; Jiang Q; Yang XP; Rhaleb NE; Zhang ZG
Stroke; 2014 Apr; 45(4):1108-14. PubMed ID: 24549864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
